Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NJA-312
- Development stage
- Preclinical
- Lead developer
- NapaJen Pharma
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
NJA-312 is a murine-specific small interfering RNA (siRNA) therapeutic candidate developed by NapaJen Pharma. It serves as the murine orthologue for the NJA-730 program, designed for use in preclinical proof-of-concept studies. The drug utilizes NapaJen's proprietary delivery technology, which involves complexing the siRNA with schizophyllan (SPG), a β-1,3-glucan that specifically binds to Dectin-1 receptors on antigen-presenting cells (APCs) such as dendritic cells and macrophages. By targeting CD40, a critical co-stimulatory molecule, NJA-312 silences its expression to modulate the immune response. It is primarily investigated for the treatment of acute graft-versus-host disease (GvHD), where it aims to suppress the pathological activation of T cells by inhibiting APC-mediated co-stimulation.
02
Targets
CD40 (Cluster of differentiation 40 receptor)CLEC7A (Dectin-1)
Beyond the preview
Go deeper on NJA-312.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NJA-312.